Primary Objective~1. To evaluate tumour ablation following treatment(s) with intratumoural injections of tigilanol tiglate.~Secondary Objectives~To assess the safety and tolerability of intratumoural injections with tigilanol tiglate.~To evaluate disease control by assessing time to local disease recurrence from last treatment.~To evaluate the tumour recurrence rate at injected tumour sites.~To evaluate survival by assessing Progression Free Survival (PFS).~Exploratory Objectives~To assess the impact on Quality of Life (QoL).~To assess the degree of wound healing after each treatment.~To assess the tumour response in injected and non-injected tumours, based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.1.~To assess the tumour response according to intratumoural Response Evaluation Criteria in Solid Tumours (itRECIST).~To assess changes in tumour biomarkers.~To assess the tumour microenvironment.
A Phase II, open label, single arm study to assess the efficacy of intratumoural tigilanol tiglate in various head and neck solid malignancies.